Literature DB >> 15750392

HIV-1 resistance genotyping on dried serum spots.

Jean-Christophe Plantier1, Raoudha Dachraoui, Véronique Lemée, Marie Gueudin, Françoise Borsa-Lebas, François Caron, François Simon.   

Abstract

OBJECTIVE: To assess the feasibility of HIV-1 group M resistance genotyping on dried serum spots, by testing samples from previously untreated patients, patients on treatment, and patients having stopped treatment, representing a wide genetic diversity panel.
METHODS: Serum samples from 62 HIV-1-infected Caucasian and African patients, with viral load values from 715 copies/ml to more than 750,000 copies/ml, were deposited on filter paper. After elution and RNA extraction, nested RT-PCR was used to amplify the protease and RT regions of the pol gene. Resistance sequencing was performed on all the protease and RT amplicons. The sequences obtained for resistance genotyping were used for subtyping by phylogenetic analysis.
RESULTS: Amplification was successful in the protease region in 53/62 cases (85.5%) and in the RT region in 51/62 cases (82.3%). All samples with viral loads of at least 5 Log (17 of 62) were successfully amplified in both the RT and protease regions. Of the 29 samples with viral loads between 4 Log and 5 Log, 28 (97%) were amplified in the RT region and 25 (86%) in the protease region. The detected mutations were in keeping with the treatment status. Marked natural polymorphism was observed in the protease region, but no major consequences were deduced in terms of resistance. The results showed a broad diversity of the panel, including subtype B (n = 36) and non B or recombinant forms (n = 20).
CONCLUSION: Our results show the feasibility of this dried serum spot method for monitoring resistance to antiretroviral drugs and the molecular epidemiology of HIV diversity. The simplicity of sample preparation, storage and transport potentially makes this an importance tool for individual and epidemiological monitoring throughout the world.

Entities:  

Mesh:

Year:  2005        PMID: 15750392     DOI: 10.1097/01.aids.0000161768.98534.e7

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  22 in total

1.  Baseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide.

Authors:  Agnès Depatureaux; Charlotte Charpentier; Gilles Collin; Marie Leoz; Diane Descamps; Aurélia Vessière; Florence Damond; Dominique Rousset; Françoise Brun-Vézinet; Jean-Christophe Plantier
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

2.  Feasibility of detecting human immunodeficiency virus type 1 drug resistance in DNA extracted from whole blood or dried blood spots.

Authors:  Kim Steegen; Stanley Luchters; Els Demecheleer; Kenny Dauwe; Kishor Mandaliya; Walter Jaoko; Jean Plum; Marleen Temmerman; Chris Verhofstede
Journal:  J Clin Microbiol       Date:  2007-08-01       Impact factor: 5.948

3.  Use of dried spots of whole blood, plasma, and mother's milk collected on filter paper for measurement of human immunodeficiency virus type 1 burden.

Authors:  Workenesh Ayele; Rob Schuurman; Tsehaynesh Messele; Wendelien Dorigo-Zetsma; Yohannes Mengistu; Jaap Goudsmit; William A Paxton; Michel P de Baar; Georgios Pollakis
Journal:  J Clin Microbiol       Date:  2007-01-24       Impact factor: 5.948

4.  Virologic failure among children taking lopinavir/ritonavir-containing first-line antiretroviral therapy in South Africa.

Authors:  Tammy Meyers; Shobna Sawry; Jessica Y Wong; Harry Moultrie; Francoise Pinillos; Lee Fairlie; Gert van Zyl
Journal:  Pediatr Infect Dis J       Date:  2015-02       Impact factor: 2.129

5.  Continuous spread of HIV-1 subtypes D and CRF01_AE in France from 2003 to 2009.

Authors:  Denys Brand; Françoise Cazein; Florence Lot; Sylvie Brunet; Damien Thierry; Alain Moreau; Josiane Pillonel; Caroline Semaille; Francis Barin
Journal:  J Clin Microbiol       Date:  2012-05-02       Impact factor: 5.948

6.  Performance of the Liaison XL Murex HIV Ab/Ag test on clinical samples representing current epidemic HIV variants.

Authors:  Véronique Lemee; Marie Leoz; Manuel Etienne; Fabienne De Oliveira; Jean-Christophe Plantier
Journal:  J Clin Microbiol       Date:  2014-06-25       Impact factor: 5.948

7.  Dried-plasma transport using a novel matrix and collection system for human immunodeficiency virus and hepatitis C virus virologic testing.

Authors:  R M Lloyd; D A Burns; J T Huong; R L Mathis; M A Winters; M Tanner; A De La Rosa; B Yen-Lieberman; W Armstrong; A Taege; D R McClernon; J L Wetshtein; Brian M Friedrich; Monique R Ferguson; William O'Brien; P M Feorino; M Holodniy
Journal:  J Clin Microbiol       Date:  2009-03-25       Impact factor: 5.948

8.  Alternative Sample Types for HIV-1 Antiretroviral Drug Resistance Testing.

Authors:  Dolly Singh; Adit Dhummakupt; Lilly Siems; Deborah Persaud
Journal:  J Infect Dis       Date:  2017-12-01       Impact factor: 5.226

9.  Evaluation of different RNA extraction methods and storage conditions of dried plasma or blood spots for human immunodeficiency virus type 1 RNA quantification and PCR amplification for drug resistance testing.

Authors:  Marjorie Monleau; Céline Montavon; Christian Laurent; Michel Segondy; Brigitte Montes; Eric Delaporte; François Boillot; Martine Peeters
Journal:  J Clin Microbiol       Date:  2009-02-04       Impact factor: 5.948

Review 10.  Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus.

Authors:  Martin Stürmer; Hans Wilhelm Doerr; Lutz Gürtler
Journal:  Med Microbiol Immunol       Date:  2009-06-04       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.